Citi analyst David Hoang lowered the firm’s price target on Denali Therapeutics (DNLI) to $27 from $32 and keeps a Buy rating on the shares. The firm noted that Denali shares traded down roughly 7% on Friday after partner Sanofi (SNY) disclosed that the Phase 2 HIMALAYA study failed to meet its primary endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics’ ALS Drug Fails Phase 2, Yet MS Trial Continues
- Denali announces data, expansion of BBB-crossing enzyme replacement therapy
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- Denali Therapeutics announces key anticipated 2024 milestones, priorities
